Prelude, Merck strike clinical trial collaboration and supply pact (NASDAQ:PRLD)
2024-07-09
Sundry Photography/iStock Editorial via Getty Images Prelude Therapeutics (NASDAQ:PRLD) has forged a deal with Merck (NYSE:MRK) to test its investigational SMARCA2 degrader in combination with the latter’s blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with SMARCA4-mutated cancers. Shares of Prelude Therapeutics (PRLD) climbed as much as 28% following the news.Continue Reading